Conclusions
With new compounds the needs of the following groups must all be satisfied, given that the needs of the patient must always remain paramount: (i) the clinical pharmacologist studying the effects of aging on drug metabolism and disposition; (ii) the pharmaceutical company planning clinical trials; (iii) the regulatory authorities wishing to ensure no drug granted a licence will subsequently be found to show unacceptable toxicity that may have been highlighted by closer study of pharmacokinetic parameters at an early stage; and (iv) the physician in hospital or family practice who wants to prescribe safely. Pharmacokinetic studies will generally be required in each case. It seems likely that the present pattern of conducting pharmacokinetic studies in the elderly will continue, but with the possible addition of more population-based studies aimed at minimising the risk of toxicity in individual patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bird HA. Drugs and the elderly. Annals of the Rheumatic Diseases 49: 1021–1024, 1990
Campbell DB, Ings RMJ. New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicology 7: 469–479, 1988
Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. British Journal of Clinical Pharmacology 7: 49–54, 1979
Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. British Medical Journal 1: 10–12, 1977
Crome P, Flanagan RJ (Eds). Drugs and the ageing population. Current issues. Journal of the Royal Society of Medicine (Suppl.), in press, 1994
Crome P, Wijayawardhana P, Guy L, Flanagan RJ, Streete PJ. Salicylate pharmacokinetics after single and multiple doses of Nu-Seals aspirin (300 mg) in young and elderly male and female volunteers. Drug Investigation 3: 252–257, 1991
Cutler NR, Narang PK (Eds). Drug studies in the elderly: methodological concerns, pp. 1–438, Plenum Medical Book Company, New York, 1986
Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clinical Pharmacokinetics 17: 236–263, 1989
Denham MJ, George CF (Eds). Drugs in old age: new perspectives, pp. 1–299, Churchill Livingstone, Edinburgh, 1990
Flanagan RJ, Johnston A, White AST, Crome P. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. British Journal of Clinical Pharmacology 28: 463–469, 1989
Jackson SHD. Pharmacodynamics. In Crome & Flanagan (Eds) Drugs and the ageing population. Current issues. Journal of the Royal Society of Medicine (Suppl.), in press, 1994
Kangas L, Iisalo E, Kanto J, Lehtinen V, Pynnöen S, et al. Human pharmacokinetics of nitrazepam: effect of age and diseases. European Journal of Clinical Pharmacology 15: 163–170, 1979
O’Malley K, Crooks J, Duke E, Stevenson IH. Effect of age and sex on human drug metabolism. British Medical Journal 3: 607–609, 1971
Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. Journal of Pharmaceutical Medicine 1: 121–128, 1991
Sheiner LB, Beal SL. Evaluation of models for estimating population pharmacokinetic parameters. Michaelis-Menten model: routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 8: 553–571, 1980
Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. British Journal of Clinical Pharmacology 32: 735–739, 1991
Thomson AH, Tucker GT. Gerontokinetics — a reappraisal. British Journal of Clinical Pharmacology 33: 1–2, 1992
Tregaskis BF, Stevenson IH. Pharmacokinetics in old age. In Denham & George (Eds) Drugs in old age: new perspectives, pp. 9–21, Churchill Livingstone, Edinburgh, 1990
Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clinical Pharmacology and Therapeutics 18: 425–432, 1975
Woodhouse KW. Hepatic drug metabolism and ageing. In Crome & Flanagan (Eds) Drugs and the ageing population. Current issues. Journal of the Royal Society of Medicine (Suppl.), in press, 1994
Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. In Denham & George (Eds) Drugs in old age: new perspectives, pp. 22–35, Churchill Livingstone, Edinburgh, 1990
Wynne HA, Cope LH, James OFW, Rawlins MD, Woodhouse KW. The effect of age and frailty upon acetanilide clearance in man. Age and Ageing 18: 415–416, 1989
Zhou HH, Whelan E, Wood AJJ. Lack of effect of ageing on the stereochemical disposition of propranolol. British Journal of Clinical Pharmacology 33: 121–123, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crome, P., Flanagan, R.J. Pharmacokinetic Studies in Elderly People. Clin. Pharmacokinet. 26, 243–247 (1994). https://doi.org/10.2165/00003088-199426040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199426040-00001